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Abstract
Antiviral responses are activated rapidly after viral infection in order to control and prevent 
dissemination of the virus. Different pathways are activated in the immune system, including innate and 
adaptive responses. On the other hand, viruses have evolved specifi c strategies to evade these responses. 
Due to the high viral evolutionary rates, escape variants can emerge and spread fast in the population. The 
co-evolution between viruses and their host is a constant arms race, and is of special interest to understand 
the viral escape mechanisms that may guide the future development of antiviral treatments and vaccines.
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https://www.peertechz.com parts of the virus in terms of their interaction with the immune 
system. For example, neutralizing antibodies can recognize 
specifi c motifs of the viral capsids that will induce the specifi c 
control of the viral infection. In case of enveloped viruses, these 
functions are exerted by the viral envelop. Due to the nature 
of the viruses, and the fact that viral populations are highly 
heterogeneous, viral populations are continuously evolving 
to try to escape immune system recognition. It is important 
to note that evolution has been driving viruses to develop 
mechanisms to avoid their recognition and their elimination 
by the host immune responses [4].
There are many mechanisms involved in immune evasion, 
including those that enable the virus to avoid recognition 
by the innate immune system, interfere with the cellular 
immune responses, and interfere with the immune effector 
function between others. A large spectrum of possibilities 
has been explored by different viruses to escape the immune 
response. Viral escape strategies are broad, and viruses have 
developed different ways to avoid being recognized by the 
immune system, as well to decrease the immune response by 
blocking specifi c pathways implicated in antiviral activities. 
Understanding viral evasion strategies to evade or antagonize 
host antiviral responses could help in the future design of 
vaccines or antiviral therapies. In this review, I am going to 
summarize some of the specifi c strategies that viruses have 
evolved to escape the pressure exerted by the human immune 
system, including innate and adaptive immune responses 
(Figure 1).
Immune responses to infection
After infection of a new host, at the early phase of infection, 
innate immune responses with an antigen independent manner 
will be turn on in the host to try to control the infection. This 
fi rst step will mainly include macrophages, Natural Killer (NK) 
cells, and dendritic cells. These cells will produce infl ammatory 
Introduction
A virus can be defi ned as an infectious agent that needs a 
host machinery to replicate and induce progeny. As non-living 
entities, viruses encounter a host, penetrate, and interact with 
the cellular equipment to produce new viruses. Viruses can 
infect all known cellular types, including archaea, bacteria, 
and eukaryotes (including plants and animals), although this 
review will focus on human viruses. Interestingly, viruses are 
highly specifi c, and will be recognized by specifi c cell receptors, 
where they will be able to attach, enter into the specifi c cell, 
and replicate. How the immune system is activated to control 
viral infections and understanding how viruses can escape an 
immune response is of special interest for the fi ght against many 
diseases. Strong immunity will suppress immune escape due to 
limiting transmission, while weak immunity will not allow for 
selection of escape variants [1]. It is important remember that 
viruses, due to their small genome sizes and short replication 
times, have high mutation rates (and evolutionary rates) that 
allow them to evolve and adapt fast to variable environments, 
and to selective pressures such as the immune system [2].
Viruses have capsids for various different activities. Firstly, 
capsids allow the virus to resist environmental conditions, 
sheltering the genome and protecting it. In addition, viral 
capsids will be recognized by specifi c cell receptors, conferring 
the opportunity for the virus to interact with and infect a 
specifi c cell type. For these reasons, viral capsids are under 
strong selective pressure and the correct packaging of the virus 
will be highly constrained [3]. However, capsids are exposed 
to the environment, and are also one of the most important 
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factors that will act as chemical messengers, including 
cytokines and chemokines. One of the most important factors 
is the production of interferon (IFN), which will activate the 
antiviral immune responses in a fast and effective manner. In a 
fi rst step, Pattern Recognition Receptors (PRRs) will recognize 
a pathogen as a foreign particle due to the interaction with 
Pathogen-Associated Molecular Patterns (PAMPs). The 
most studied PRRs are the toll-like receptors (TLRs), which 
recognize microbial PAMPs. Other PRRs implicated in viral 
recognition are the RIG-like receptors (RLRs), the cyclic gMP-
AMP synthase (cGAS), and the IFN-ɣ-inducible protein 16 
(IFI16). The interaction of viral ligands with host receptors 
activates downstream signaling events that will in turn activate 
transcription factors, that ultimately regulate the expression 
of genes implicated in innate and adaptive immunity [5]. For 
example, if a TLR recognizes a PAMP, a cascade of signals will 
be activated and will induce the production of cytokines, mostly 
type I IFN, that will promote the maturation of dendritic cells 
and regulate macrophages, NK cells, and T and B cells. At this 
point, the effi cacy of host responses will be strongly dependent 
on a rapid and specifi c recognition of the pathogen, in order 
to rapidly activate the fi rst barrier response to control the 
infection. 
At the late phase of infection, adaptive immune responses 
are activated. These responses are highly specifi c to a 
particular pathogen, in contrast with the innate immune 
ones. Furthermore, adaptive responses provide a long-lasting 
protection against the specifi c pathogen. Adaptive responses 
are carried out by lymphocytes, and there are two main classes 
of response: antibody responses, and cell-mediated immune 
responses. Antibody responses are mainly carried out by B 
cells secreting immunoglobulins, while cell-mediated immune 
responses are under T cell control. Adaptive immune responses 
are basically dependent on the major histocompatibility 
complex (MHC) class I and II. Adaptive immune responses are 
shaped by the quality of the initial innate immune responses 
[6].
Viral evasion of innate immune responses
Due to the short replication times in viruses, and to their 
high mutation rates, viruses can evolve and adapt quickly 
to the immune responses to evade them and continue the 
infection. At fi rst, innate immune responses will be activated 
which are not pathogen specifi c. Viruses should evade the 
mucosal physical barrier to succeed in their entry, and this 
breakdown is considered a crucial event causing immune 
activation [7]. Viruses should also override innate responses 
as the complement system to increase viral spread. To favor 
their replication and survival, viruses should also combat IFN 
responses and modulate or mimic cytokines and chemokines 
that will allow the viruses to create a persistent infection. 
Finally, blocking cellular functions as pDC or NK cells are also 
targets for viral evasion.
Evasion of immune sensing pathways: PRRs can recognize a 
large number of PAMPs including lipopolysaccharide, bacterial 
endotoxins, fl agellins, peptidoglycan, and non-self nucleic 
acids, among others [8]. For this reason, viral nucleic acids 
can be rapidly recognized as PAMPs and trigger an immune 
response. Many strategies used by viruses to evade innate 
immune responses are mediated by sensors as RLRs, cGAS 
or IFI16, and successful viruses need to evade or inhibit the 
activation of intracellular PRRs. Altering or hiding their nucleic 
acids are strategies to escape immune responses. Inducing the 
formation of specifi c replication compartments confi ned by 
cellular membranes, or replicating inside organelles, prevents 
RLRs from accessing viral nucleic acids. In addition, some 
viruses have evolved ways to degrade RIG-I via ubiquitylation 
to inhibit their signal cascade, while others encode for viral 
proteases that directly cleave RLRs. In the end, the IFN cascade 
is blocked and the production of IFNs is prevented. Another 
strategy is to relocalize RLRs into virus-induced structures to 
sequester RLRs and prevent their antiviral responses. cGAS has 
been recognized as an intracellular sensor that activates the 
IFN pathway in response to a viral infection, and again, viruses 
have evolved mechanisms to inhibit such a response [9].
For example, the Hepatitis C Virus (HCV) has evolved 
multiple mechanisms to inhibit IFN antiviral activity, and 
the expression of HCV proteins blocks the transcriptional 
response to IFN- [10]. IFI16 has been linked, as well, to innate 
immunity against viruses, and can serve as nuclear or cytosolic 
sensor of DNA, playing a role in inducing the infl ammasome 
[11]. Human cytomegalovirus (HCMV) has developed evasion 
strategies to counteract the effects of IFI16. HCMV expresses 
a protein that will phosphorylate IFI16, promoting its nucleo-
cytoplasmic relocalization and thus removing IFI16 from the 
site of restriction activity. It has been also shown that HCMV 
incorporates IFI16 into newly formatted virions to expulse it 
from the cell altogether, thereby evading the IFI16 antiviral 
activity [12]. Infl uenza virus type A (IAV) is able to antagonize 
the innate host response by the expression of the non-
structural protein 1 (NS1). NS1 is a multifunctional virulence 
factor that interferes with the RIG-I cascade, and also has a 
strong impact on gene products induced by viral infection like 
IFN and pro-infl ammatory cytokines and chemokines [13]. 
Dengue virus (DENV) and West Nile virus (WNV) are able to 
block type I IFN expression by escaping recognition of PRRs, 
or by actively inhibiting PRR-mediated IFN-/ induction. 
Their evasion strategies consist basically of a sequestration or 
modifi cation of viral RNA, direct inhibition of PRRs or adaptor 
proteins, and antagonism of key signaling proteins downstream 
Figure 1: Schematic representation of the main responses to viral infection. 
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of PRRs [14]. Epstein-Barr virus (EBV) inhibits cellular protein 
synthesis in productively infected cells through global mRNA 
destabilization, and can affect immunological relevant proteins 
including TLR2 and TLR9 that are capable of sensing EBV 
infection. Shutoff-induced reduction in protein levels mainly 
prevent production of newly synthesized effector molecules, 
rather than reducing the levels of existing PRRs [15]. 
Evasion of immune effector functions: Viruses have evolved 
to modulate immune effector functions, including cytokines, 
chemokines or complement actions. For example, IL-10 is a 
potent immunosuppressive and anti-infl ammatory cytokine. 
HCMV has evolved to express a homologue of IL-10 in order 
to decrease the immune response [16], while retaining the 
activities that are advantageous for the virus. Some viruses are 
able to express chemokine receptor homologues, implicated in 
viral pathogenesis sequestering chemokines, to limit effector 
cell activation [17,18].
Among the cytokines, IFNs have a major role in virus 
infection. They induce immune activation and enhance antigen 
presentation, and also have antiviral activity [19]. Recognition 
of PAMPs stimulates the activation of IFN-induced signaling 
pathways, leading to the production of proinfl ammatory 
cytokines and chemokines and antiviral type I IFN. Viruses 
have developed many strategies to alter the expression of 
IFN-stimulated genes, blocking multiple levels of IFN-signal 
transduction [19]. Some EBV gene products interfere with the 
function of innate effector molecules. For example, BARF1 
neutralizes the effect of host cytokines, leading to reduced 
IFN- secretion [20], and BZLF1 is able to downregulate the 
receptors for IFNs to reduce cellular responses to cytokines, as 
well as inducing a suppressor of cytokine signaling which again 
reduces IFN type I production [15]. It is interesting to note that 
the major sources of IFN are the plasmacytoid dendritic cells 
(pDCs), which play a central role in the innate immune response. 
Human immunodefi ciency virus (HIV) inhibits the pDC counts 
in peripheral blood, and gp120 suppresses pDC activation and 
production of cytokines, inhibiting IFN production [7].
Viral interference with the complement system has been 
also described. The complement system, a major host defense 
mechanism, triggers the recruitment of infl ammatory cells and 
induces the formation of pores in the plasma membranes of 
target cells. Many viruses have developed different strategies 
to overcome the effects of the complement and increase viral 
spread. Some viruses can express structural viral proteins that 
mimic the function of the cellular regulators of the complement 
activation (RCA). Others are able to incorporate host RCA into 
their envelope by budding through the plasma membrane 
or into intracellular vacuoles, and some viruses even secrete 
proteins that directly block complement activation [21]. Infected 
cells can be also lysed via antibody-dependent complement-
mediated lysis. For example, the regulatory factor CD59 
present in HIV prevents complement mediated neutralization 
of antibody bound viruses [22]. Additionally, gp41 and gp120 
HIV envelope proteins interact with complement proteins, and 
this causes decreased complement dependent lysis of infected 
cells [23]. 
Evasion of NK cell-mediated immune response: NK cells 
are an important initial defense against many viral infections. 
NK cells release cytotoxic granules containing perforin and 
granzymes into infected cells to lyse them. NK cells can also 
bind to specifi c apoptosis-inducing receptors on target cells to 
induce cell death [24]. NK cell regulation is dependent on a 
fi ne balance between activating (Ly49D, Ly49H and NKG2D) 
and inhibitory (killer immunoglobulin-like receptors (KIR), 
immunoglobulin-like transcripts (ILT), and CD94-NKG2D) 
cell surface receptors [10]. These receptors bind to host MHC-I 
molecules and transmit inhibitory signals to the NK cell. NK cell 
target recognition occurs after ligation of activating receptors 
and repression of inhibitory receptors on the cell surface, and is 
activated during a wide variety of viral infections by type I IFN. 
Viruses have developed different approaches in order to avoid 
NK cell responses. Many viruses express MHC-I homologues, 
while others evade NK cell responses by increasing surface 
expression of MHC-I molecules. HIV Nef protein has been 
postulated as a potential regulator of NK cell cytotoxicity due 
to its involvement in MHC-I downregulation on CD4+ cells, 
conferring an additional evasion strategy against NK cells 
[20]. Virus-mediated inhibition of activating receptor function 
and production of virally encoded cytokine-binding proteins 
or cytokine-receptor antagonists are other approaches to 
circumvent the action of NK cells [24].
Viral evasion of adaptive immune responses
Adaptive antiviral immunity is activated after innate 
responses, and the quality of these initial innate immune 
responses will defi ne the effectiveness of the adaptive 
responses [6]. This adaptive immunity relies on the memory-
based response of virus-specifi c B- and T-cells. Detection and 
elimination of infected cells is the ultimate goal, and virus-
specifi c T-cell responses involve the activation of CD8+ and 
CD4+ T-cells by interfering with the MHC-I and -II antigen 
presentation pathways.
Evasion of neutralizing antibodies: Neutralizing antibodies 
(nAbs) have specifi c roles in preventing, reducing, and clearing 
infection. Neutralization prevent viral entry into cells, mainly 
by recognition of specifi c regions of the viral capsid or envelope 
proteins, conformational epitopes, and glycans [25].
Many viruses display low levels of diversity at the amino 
acid level compared to their nucleotide diversity. Overall, 
capsid genes are highly constrained to maintain proper capsid 
folding. Furthermore, many viruses encode capsid residues by 
rare codons that are highly conserved and, in some cases, close 
to potential epitopes. This is the case for the hepatitis A virus 
(HAV), where only a few antigenic variants have been isolated 
in nature, suggesting some strong capsid constraints limiting 
antigenic variability [26]. For these reasons, even under 
immune pressure, substitutions in these specifi c residues is 
negatively selected.
Bad vaccine administration can favor the selection of 
variants able to escape immune system recognition, for 
example via escape of antibody neutralization despite their 
lower fi tness compared to other viral variants. Due to the large 
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population sizes of viruses, and despite the presence of nAbs, 
it has been shown that replication under restricted conditions 
favors the selection of resistant mutants and leads to the 
emergence of new serotypes, despite genomic, structural or 
biological constraints. In general, these mutants will have a 
selective advantage in the presence of nAbs, and lower fi tness in 
permissive conditions (absence of the antibody). However, this 
process can have unknown consequences due to the emergence 
of new variants with different pathogenic properties.
One of the most studied viruses, due to previous pandemics 
and its rapid acquisition of resistance to anti-viral B cell 
immunity, is IAV. The action of NAbs against the IAV major 
surface protein (hemagglutinin) is one of the best studied 
immune responses. IAV has developed two forms of antigenic 
variation to escape neutralization [15]. One of them is antigenic 
drift, in which the introduction of point mutations in the 
genes encoding for the hemagglutinin and neuraminidase 
can produce specifi c mutations in the interaction sites and 
lead to escape variants, due to the impairment of binding 
of the antibody to the epitope. The error prone polymerase 
allows the generation of a swarm of mutants, leading to the 
selection of escape-mutants. The other process is known as 
antigenic shift, in which RNA segments are exchanged (re-
assortment) between two different virus strains during double 
infection of one host cell, which can lead to major changes in 
the hemagglutinin protein and block antibody recognition of 
the virus [13]. This is one of the known strategies to rapidly 
change viral surface protein composition, and can lead to the 
generation of pandemic IAV strains.
Besides changes in the amino acid composition of the 
surface proteins, some viruses like IAV and HIV have developed 
post-transcriptional modifi cations, mainly glycosylation, 
that change the accessibility and function of the viral surface 
proteins and help with evasion of immune responses. These 
modifi cations have important implications in receptor binding, 
viral infectivity, and virus release. It is important to note that 
glycosylation can reduce viral pathogenicity if it is close to 
receptor-binding sites [27].
Evasion of the T-cell-mediated immune response: Cell-
mediated immune responses by T cells are also a target for viral 
evasion. Viruses can impair activation of CD8+ and CD4+ T cells 
by blocking the presentation of antigen in the context of the 
MHC class I and II molecules, respectively. MHC-I molecules 
are able to present peptides that have been degraded by the 
proteasome in the cytosol of the cell. Proteasome degradation 
starts with the ubiquitylation of a protein, and is dependent 
on proteolytic cleavage of a specifi c sequence in the protein to 
degrade. Mutations in these specifi c motifs allows the virus to 
not cleave the protein in the correct positions, and to impair 
peptide presentation [28]. Studies with EBV support that 
changes in protein folding can block the entry to the proteasome 
complex [29]. In addition, phosphorylation of specifi c residues 
of HCMV proteins can also restrict the access of the protein to 
proteasome degradation, or divert the protein into a different 
degradation pathway [30]. In a second step, peptides pass the 
endoplasmic reticulum (ER) membrane, translocated via the 
transporter associated with antigen presentation (TAP), to be 
presented by the MHC-I complexes. HMCV expresses a protein 
able to inhibit TAP and retains the peptides that will not be 
translocated and presented by MHC-I [31]. Other viruses have 
developed other strategies to block the activity of TAP, like the 
herpes simplex virus (HSV) [32] or EBV, in which expression of 
BNLF2a results in a reduced CD8 + T-cell recognition through 
inhibition of peptide import by TAP [15].
In IAV, it has been shown that although escape mutations 
in MHC-I epitopes seems to occur less often than in epitopes 
of neutralizing antibodies, substitution in the anchor residues 
can lead to a loss of the binding to the respective MHC-I 
molecule, or decrease the avidity to the T-cell antigen receptor 
by mutations in the interacting residues [13]. Another strategy 
of EBV to inhibit T-cell recognition is the expression of BGLF5, 
which degrades MHC-I encoding mRNAs, reducing peptide 
presentation at the cell surface [15].
Other strategies reside in the prevention of MHC-I 
formation. HCMV is able to express a protein that will retain 
the MHC-I peptide complexes in the ER, which will then not 
be expressed at the surface of the cells [31]. Viruses such as 
varicella-Zoster virus (VZV) or HIV have viral products with a 
similar function. In addition, HCMV and human herpes virus-8 
(HHV-8) express some proteins implicated in the degradation 
of MHC-I molecules in a proteasome-dependent manner 
[33,34]. EBV is able to downregulate surface MHC-I molecules 
by BILF1, reducing transport of MHC-I molecules from the 
Golgi, and also enhancing degradation via lysosomal proteases 
[35].
Antigenic variation also has a strong impact on T-cell 
responses. It has been already shown that cleavage of the 
peptides is sequence-dependent, and alteration of peptide 
binding to MHC can create unstable peptide-MHC complexes, 
as demonstrated in HIV or the hepatitis B virus (HBV). Finally, 
some viruses are able to downregulate T-cell receptors 
complexes in T-cells [36].
Viral peptides can also be presented by the MHC-II. 
In general, MHC-II is able to present antigens derived 
from exogenous proteins that are endocytosed, degraded 
in lysosomes, and then delivered to the MHC-II loading 
compartment [37]. Viruses like HCMV and VZV have evolved 
mechanisms in order to downregulate MHC-II expression, to 
reduce the antigen presentation. Downregulation of MHC-
II inhibits Th-cell activation and, indirectly, the antibody 
production by plasma cells. CD4+ T-cells against lytic antigens 
are also found in the peripheral blood of infected individuals. 
For example, EBV uses entry receptor Gp42, which binds 
to MHC-II molecules present on B-cells, but also acts as an 
immune evasion molecule blocking T-cell receptors (TCRs) 
class II interactions, precluding activation of CD4+ T-cells. In 
addition, BGLF5 decreases MHC-II molecules at the cell surface 
via degradation of MHC-II mRNAs, as also occurs for MHC-I 
[15].
Finally, it is important to mention the action of the 
programmed cell death protein (PD-1), an immunoglobulin 
that regulates T cell responses. PD-1 expression is usually 
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modulated by cytokines, and induced through TCRs, although 
it has been reported in other cells like B cells, NKs, or DCs. His 
role in the evasion of tumor cells has been extensively described, 
although also regulates antiviral immunity. Viruses have 
developed different mechanisms to modulate PD-1 expression, 
usually mediated by upregulation of PD-1 and its ligands PD-
L1 and PD-L2, as has been observed during infection caused 
by many viruses such as HIV, HCV, or HBV. However, although 
PD-1/PD-L1 impact in chronic viral infections has been well 
described, their impact in early infections is still under study 
[38]. It has been shown that T cell exhaustion in chronic viral 
infections unable to clear the persistent infections due to the 
upregulation of PD-1, and recent works show the potential 
of PD-1 therapy to rescue T cells and control the virus [39]. 
Nevertheless, how viruses modulate these responses as a viral 
evasion mechanism, or if it represents an adaptation of the 
host defenses is still controversial, and further efforts in this 
fi eld are mandatory to determine the nature of this interaction.
Conclusion
Viruses are constantly under immune system pressure, 
leading to the emergence of new variants that allow them to 
escape. Due to the wide range of options that the immune 
system has to block viral infections, viruses have evolved 
different mechanisms to escape from almost all the possible 
pathways. Understanding viral evolution and escape strategies 
for the specifi c pathways or molecules is of special interest in 
the development of antiviral drugs or vaccines. For example, 
identifi cation of epitopes that escape rapidly to the virus-
specifi c T-cells is of special interest for the production of 
epitope-based vaccines. Further efforts should be undertaken 
in order to better understand viral escape strategies at the 
molecular level, as well as how host cells evolve to thwart viral 
immune escape.
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